5 related articles for article (PubMed ID: 38758397)
1. Efficacy and Safety of Taletrectinib in Chinese Patients With
Li W; Xiong A; Yang N; Fan H; Yu Q; Zhao Y; Wang Y; Meng X; Wu J; Wang Z; Liu Y; Wang X; Qin X; Lu K; Zhuang W; Ren Y; Zhang X; Yan B; Lovly CM; Zhou C
J Clin Oncol; 2024 Jun; ():JCO2400731. PubMed ID: 38822758
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.
Nosaki K; Yoh K; Toyozawa R; Horinouchi H; Morise M; Ohashi K; Murakami H; Satouchi M; Sakakibara-Konishi J; Yano S; Okumura F; Matsumoto S; Shimokawa M; Seto T; Goto K
Int J Clin Oncol; 2024 May; ():. PubMed ID: 38758397
[TBL] [Abstract][Full Text] [Related]
3.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
4.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
5.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
